Supporting evidence in phase 2 cancer trial protocols: a content analysis
Supporting evidence is key to justifying the commitment of scientific resources and patients to a clinical hypothesis. Protocols often omit elements that would enable critical assessment of supporting evidence for phase 2 monotherapy cancer trials. These gaps suggest the promise of more structured approaches for presenting supporting evidence.
Authors
- Angela Nelson (ORCID: https://orcid.org/0000-0002-4848-5217)
- Jonathan Kimmelman (ORCID: https://orcid.org/0000-0003-1614-6779)
- Selin Bicer (ORCID: https://orcid.org/0000-0002-5532-1974)
- Katerina Carayannis
Institutions
- Ethics and Public Policy Center (US)
- McGill University (CA)
Publication Details
- Journal
- JNCI Journal of the National Cancer Institute
- Published
- 2024-11-12
- DOI
- https://doi.org/10.1093/jnci/djae281
- Primary Topic
- Statistical Methods in Clinical Trials
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Canadian Institutes of Health Research